Hubei Goto Biopharm Group Co., Ltd. (SHE:300966)

China flag China · Delayed Price · Currency is CNY
29.15
+0.48 (1.67%)
Jul 15, 2026, 3:06 PM CST
Market Cap3.27B +56.7%
Revenue (ttm)628.90M +13.6%
Net Income-71.24M
EPS-0.62
Shares Out 114.21M
PE Ration/a
Forward PEn/a
Dividend0.05 (0.16%)
Ex-Dividend DateJul 16, 2026
Volume7,245,153
Open28.50
Previous Close28.67
Day's Range28.17 - 29.70
52-Week Range18.44 - 32.58
Beta0.45
Analystsn/a
Price Targetn/a
Earnings DateAug 26, 2026

About Hubei Goto Biopharm Group

Hubei Goto Biopharm Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid drug raw materials in China and internationally. It offers starting materials, intermediates, and other pharmaceutical raw materials. The company was formerly known as Hubei Goto Biopharm Co.,Ltd. and changed its name to Hubei Goto Biopharm Group Co., Ltd. in June 2026. The company was founded in 2006 and is based in Xiangyang, China. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 893
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300966
Full Company Profile

Financial Performance

In 2025, Hubei Goto Biopharm Group's revenue was 606.18 million, an increase of 12.97% compared to the previous year's 536.60 million. Losses were -73.36 million, 165.9% more than in 2024.

Financial Statements